Tags

Type your tag names separated by a space and hit enter

Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays.
PLoS One. 2020; 15(10):e0240395.Plos

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) is an emerging threat worldwide. This study aims to assess the serologic profiles and time kinetics of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with COVID-19 using two immunoassays.

METHODS

A total of 97 samples serially collected from 17 patients with COVID-19 and 137 negative control samples were analyzed for IgM and IgG against SARS-CoV-2 using the AFIAS COVID-19 Ab (Boditech Med Inc., Chuncheon, Republic of Korea) and the EDI™ Novel Coronavirus COVID-19 ELISA Kit (Epitope Diagnostics, Inc., San Diego, CA).

RESULTS

With both assays, IgM and IgG rapidly increased after 7 days post symptom onset (PSO). IgM antibody levels reached a peak at 15-35 d PSO and gradually decreased. IgG levels gradually increased and remained at similar levels after 22-35 d. The diagnostic sensitivities of IgM/IgG for ≤14d PSO were 21.4%/35.7~57.1% and increased to 41.2~52.9%/88.2~94.1% at >14 d PSO with specificities of 98.5%/94.2% for AFIAS COVID-19 Ab and 100.0%/96.4% for EDI™ Novel Coronavirus COVID-19 ELISA Kit. Among 137 negative controls, 12 samples (8.8%) showed positive or indeterminate results.

CONCLUSIONS

The antibody kinetics against SARS-CoV-2 are similar to common findings of acute viral infectious diseases. Antibody testing is useful for ruling out SARS-CoV-2 infection after 14 d PSO, detecting past infection, and epidemiologic surveys.

Authors+Show Affiliations

Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33091042

Citation

Kweon, Oh Joo, et al. "Antibody Kinetics and Serologic Profiles of SARS-CoV-2 Infection Using Two Serologic Assays." PloS One, vol. 15, no. 10, 2020, pp. e0240395.
Kweon OJ, Lim YK, Kim HR, et al. Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays. PLoS One. 2020;15(10):e0240395.
Kweon, O. J., Lim, Y. K., Kim, H. R., Kim, M. C., Choi, S. H., Chung, J. W., & Lee, M. K. (2020). Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays. PloS One, 15(10), e0240395. https://doi.org/10.1371/journal.pone.0240395
Kweon OJ, et al. Antibody Kinetics and Serologic Profiles of SARS-CoV-2 Infection Using Two Serologic Assays. PLoS One. 2020;15(10):e0240395. PubMed PMID: 33091042.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays. AU - Kweon,Oh Joo, AU - Lim,Yong Kwan, AU - Kim,Hye Ryoun, AU - Kim,Min-Chul, AU - Choi,Seong-Ho, AU - Chung,Jin-Won, AU - Lee,Mi-Kyung, Y1 - 2020/10/22/ PY - 2020/07/01/received PY - 2020/09/27/accepted PY - 2020/10/22/entrez PY - 2020/10/23/pubmed PY - 2020/11/11/medline SP - e0240395 EP - e0240395 JF - PloS one JO - PLoS One VL - 15 IS - 10 N2 - BACKGROUND: Coronavirus disease 2019 (COVID-19) is an emerging threat worldwide. This study aims to assess the serologic profiles and time kinetics of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with COVID-19 using two immunoassays. METHODS: A total of 97 samples serially collected from 17 patients with COVID-19 and 137 negative control samples were analyzed for IgM and IgG against SARS-CoV-2 using the AFIAS COVID-19 Ab (Boditech Med Inc., Chuncheon, Republic of Korea) and the EDI™ Novel Coronavirus COVID-19 ELISA Kit (Epitope Diagnostics, Inc., San Diego, CA). RESULTS: With both assays, IgM and IgG rapidly increased after 7 days post symptom onset (PSO). IgM antibody levels reached a peak at 15-35 d PSO and gradually decreased. IgG levels gradually increased and remained at similar levels after 22-35 d. The diagnostic sensitivities of IgM/IgG for ≤14d PSO were 21.4%/35.7~57.1% and increased to 41.2~52.9%/88.2~94.1% at >14 d PSO with specificities of 98.5%/94.2% for AFIAS COVID-19 Ab and 100.0%/96.4% for EDI™ Novel Coronavirus COVID-19 ELISA Kit. Among 137 negative controls, 12 samples (8.8%) showed positive or indeterminate results. CONCLUSIONS: The antibody kinetics against SARS-CoV-2 are similar to common findings of acute viral infectious diseases. Antibody testing is useful for ruling out SARS-CoV-2 infection after 14 d PSO, detecting past infection, and epidemiologic surveys. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/33091042/Antibody_kinetics_and_serologic_profiles_of_SARS_CoV_2_infection_using_two_serologic_assays_ L2 - https://dx.plos.org/10.1371/journal.pone.0240395 DB - PRIME DP - Unbound Medicine ER -